RT Journal Article
SR Electronic
T1 COVID-19 Outcomes and Genomic characterization of SARS-CoV-2 isolated from Veterans in New England States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.27.21256222
DO 10.1101/2021.04.27.21256222
A1 Lee, Megan
A1 Sallah, Ya Haddy
A1 Petrone, Mary E.
A1 Ringer, Matthew
A1 Cosentino, Danielle
A1 Vogels, Chantal B.F.
A1 Fauver, Joseph R.
A1 Alpert, Tara
A1 Grubaugh, Nathan D.
A1 Gupta, Shaili
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.04.27.21256222.abstract
AB Background Clinical and virologic characteristics of COVID-19 infections in veterans in New England have not been described.Objectives To evaluate clinical and virologic factors impacting COVID-19 outcomes.Study Design We reviewed charts and sequenced virus from nasopharyngeal specimens with confirmed SARS-CoV-2 from 426 veterans in six New England states between April and September, 2020. Peak disease severity, hospitalization, and mortality were correlated to clinical, demographic, and virologic factors.Results Of 426 veterans, 274 had complete and accessible charts. 92.7% were men, 83.2% White, with mean age 63 years. On multivariate regression, significant predictors of hospitalization were age (OR: 1.05) and non-white race (OR: 2.39). Mortality and peak disease severity varied by age (OR 1.06 and 1.07 respectively) and oxygen requirement on admission (OR6.74 and 45.7). Dementia (OR: 3.44) was also associated with mortality. Most (97.3%) of our samples were dominated by the spike protein D614G substitution, and were from SARS-CoV-2 B.1 lineage or one of 37 different B.1 sub-lineages, with none representing more than 8.7% of the cases.Conclusions In an older cohort of veterans from the six New England states with a high comorbidity burden, age was the largest predictor of hospitalization, peak disease severity, and mortality. Non-white veterans were more likely to be hospitalized, and patients who required oxygen on admission were more likely to have severe disease and higher rates of mortality. Multiple SARS-CoV-2 lineages were distributed in patients in New England early in the COVID-19 era, mostly related to viruses from New York with D614G mutation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Centers for Disease Control and Prevention [BAA 75D301-20-R-68024 to N.D.G. and S.G.] and the Yale Center for Clinical Investigation TL1 TR001864 (M.E.P.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Veterans Administration (VA) Connecticut Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request